Modern oncologic treatment: For example melanoma;Moderne tumortherapie am beispiel des melanoms

Praxis

Volumn 85, Issue 50, 1996, Pages 1609-1614

  Dummer, R ^a   Nestle, F O ^a   Burg, G ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; GENE THERAPY; HUMAN; IMMUNOTHERAPY; MELANOMA; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; PROGNOSIS; REVIEW; SKIN TUMOR;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; MELANOMA; PALLIATIVE CARE; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SKIN NEOPLASMS;

EID: 0030579407     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Levi F., Franceschi S., Van-Cong T. E., Randimbison L., LaVecchia C.: Tendances des cancers de la peau dans la canton Vaud 1976-1992. Rev. Med. Suisse Romande 115, 739-746, 1995.
2. Boni R., Dummer R., Burg G.: Nehmen Hauttumoren zu? Schweiz. med. Wschr. 125, 1619-1624, 1995.
3. Haffner A. C., Garbe C., Burg G., Buttner P., Orfanos C. E., Rassner G.: The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients. Br. J. Cancer 66, 856-861, 1992.
4. Koh H. K.: Cutaneous melanoma. New Engl. J. med. 325, 171-182, 1991.
5. Burg G., Dummer R.: Maligne Melanome. In: Wilmanns W., Huhn D., Wilms K. (Hrsg.): Lehrbuch der Internistischen Onkologie. Thieme, Stuttgart, New York, S. 564-571, 1994.
6. Barnhill R. L., Mihm M. J.: The histopathology of cutaneous malignant melanoma. Semin. Diagn. Pathol. 10, 47-75, 1993.
7. Balch C., Milton G.: Cutaneous Melanoma. Lippincott, Philadelphia, 1985.
8. Balch C. M., Urist M. M., Karakousis C. P., Smith T. J., Temple W. J., Drzewiecki K., Jewell W. R., Bartolucci A. A., Mihm M. J., Barnhill R. et al.: Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multiinstitutional randomized surgical trial. Ann. Surg. 218, 262-267, 1993.
9. Barth A., Morton D. L.: The role of adjuvant therapy in melanoma management. Cancer 75, 726-734, 1995.
10. Cascinelli N., Bufalino R., Morabito A., Mackie R.: Results of adjuvant interferon study in WHO melanoma programme (letter). Lancet 343, 913-914, 1994.
11. Kirkwood J. M., Strawderman M. H., Ernstoff M. S., Smith T. J., Borden E. C., Blum R. H.: Interferon-alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma. The Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14, 7-17, 1996.
12. Willner J., Bohndorf W.: ZNS-Metastasen beim malignen Melanom. Strahlenther. Onkol. 171, 165-173, 1995.
13. Dummer R., Gore M., Hancock B., Guillou P., Grobben H., Becker J., Oskam R., Dieleman J., Burg G.: A multicenter phase II clinical trial using dacarbazine and continous infusion of interleukin-2 in metastatic melanoma. Clinical data and immunomonitoring. Cancer 75, 1038-1044, 1995.
14. Keilholz U., Scheibenbogen C., Tilgen W., Bergmann L., Weidmann E., Seither E., Richter M., Brada B., Mitrou P. S., Hunstein W.: Interferon-alpha and interleukin-2 in the treatment of metastatic malanoma. Comparison of two phase II trials. Cancer 72, 607-614, 1993.
15. Falkson C. I.: Experience with interferon-alpha-2b combined with dacarbazine in the treatment of metastatic malignant melanoma. Med. Oncol. 123, 35-40, 1995.
16. Pisha E., Chai H., Lee I. S., Chagwedera T. E., Farnsworth N. R., Cordell G. A., Beecher C. W., Fong H. H., Kinghorn A. D., Brown D. M.: Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nature med. 1, 1046-1051, 1995.
17. Brunda M. J.: Interleukin-2. J. leukoc. Biol. 55, 280-288, 1994.
18. Dummer R., Davis-Daneshfar A., Döhring C., Döbbeling U., Burg G.: Strategien zur Gentherapie des Melanoms. Hautarzt 46, 305-308, 1995.
19. Parminai G., Colombo M. P.: Somatic gene therapy of human melanoma. Preclinical studies and early clinical trials. Melanoma Res. 5, 295-301, 1995.
20. Bystryn J. C.: Immunosurveillance and melanoma. J. Invest. Dermatol. 92, S. 318-320, 1989.
21. Gutwald J., Groth W., Mahrle G.: Peritumoral appliziertes IL-2 induziert Tumorregression beim Melanom. Eine Pilotstudie. Hautarzt 45, 536-540, 1994.
22. Dummer R., Welters H., Keilholz U., Tilgen W., Burg G.: Interleukin-2 - immunologischer Hintergrund und Anwendung in der Tumor-therapie. Hautarzt 41, 53-55, 1990.
23. van der Bruggen P., Trversari C., Chomez P., Lurquin C., DePlaen E., Van den Eynde B., Knuth A., Boon T.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647, 1991.
24. Bakker A. B., Schreurs M. W., de Ba, Kawakami Y., Rosenberg S. A., Adema G. J., Figdor C. G.: Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179, 1005-1009, 1994.
25. Dummer R., Boni R.: Wie entkommen Melanomzellen der Immunantwort? Konsequenzen für zukünftige Therapieansätze und gegenwärtige Biopsieverarbeitung. Schweiz. med. Wschr. 125, 1638-1648, 1995.
26. Kruger-Krasagakes S., Krasagakis K., Garbe C., Diamantstein T.: Production of cytokines by human melanoma cells and melanocytes. Recent Results Cancer Res. 139, 155-168, 1995.
27. Lanzavecchia A.: Identifying strategies for immune intervention. Science 260, 937-944, 1993.
28. Mulligan R. C.: The basic science of gene therapy. Science 260, 926-932, 1993.
29. Döhring C., Angman L., Spagnoli G., Lanzavecchia A.: T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int. J. Cancer 57, 754-759, 1994.
30. Nestle F. O., Zheng X. G., Thompson C. B., Turka L. A., Nickoloff B. J.: Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J. Immunol. 151, 6535-6545, 1993.
31. Rankin E. M.: Scientific aspects of gene therapy in melanoma. Curr. Opin. Oncol. 7, 192-196, 1995.
32. Wills K. N., Maneval D. C., Menzel P., Harris M. P., Sutjipto S., Vaillancourt M. T., Huang W. M., Johnson D. E., Anderson S. C., Wen S. F.: Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum. Gene Ther. 5, 1079-1088, 1994.